Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Takahashi, Kiyohiko; Nakamura, Akinobu; Furusawa, Sho; Yokozeki, Kei; Sugawara, Hajime; Yanagisawa, Hideyuki; Akikawa, Kazumasa; Kikuchi, Hideaki

Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Takahashi, Kiyohiko; Nakamura, Akinobu; Furusawa, Sho et al.

Journal of Clinical and Translational Endocrinology, 2020, 22, 100244

Permalink : https://hdl.handle.net/2115/80266

このアイテムのアクセス数:506件（2026-10-07 17:06 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1016/j.jcte.2020.100244			22

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/80266
タイトル	Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria
著者	Takahashi, Kiyohiko ; Nakamura, Akinobu ; Furusawa, Sho ; Yokozeki, Kei ; Sugawara, Hajime ; Yanagisawa, Hideyuki ; Akikawa, Kazumasa ; Kikuchi, Hideaki
著者名 Takahashi, Kiyohiko
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Furusawa, Sho
著者名 Yokozeki, Kei
著者名 Sugawara, Hajime
著者名 Yanagisawa, Hideyuki
著者名 Akikawa, Kazumasa
著者名 Kikuchi, Hideaki
言語	英語
キーワード	Chronic kidney disease
	Diabetic kidney disease
	Normoalbuminuria
	Sodium-glucose cotransporter 2 inhibitor
	Type 2 diabetes
発行日	2020-12
出版者	Elsevier
収録物名	Journal of Clinical and Translational Endocrinology
巻(号)	22
ページ	100244
抄録	Introduction: We investigated the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on renal function in patients with type 2 diabetes and chronic kidney disease (CKD) with normoalbuminuria. Methods: A retrospective review of clinical records of Japanese participants with type 2 diabetes and CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m(2)) with normoalbuminuria (urine albumin to creatinine ratio < 30 mg/g Cr and/or urinary protein to creatinine ratio < 150 mg/g Cr) was conducted. Participants were categorized into two groups depending on whether they had started using SGLT2is. The main study outcome was a comparison of the change in renal function evaluated by eGFR after 1 year between the two groups. Then, we identified predictors that were associated with the outcome. Results: Among the 46 participants, 21 were treated with SGLT2is (SGLT2 group) and 25 were treated with other antidiabetic medications (control group). Although eGFR was significantly decreased at 1 year in the control group, the decline in eGFR was not observed in the SGLT2 group. The decrease in eGFR was significantly smaller in the SGLT2 group than in the control group. Additionally, multiple linear regression analysis showed that an initial dip was an independent factor associated with the worsening of renal function in the SGLT2 group. Conclusions: Although more favorable effects of SGLT2is on renal function were observed in patients with type 2 diabetes and CKD with normoalbuminuria, the higher initial dip was a possible marker of worsening renal function after the initiation of SGLT2is.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN	2214-6237
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1016/j.jcte.2020.100244